Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Jan;71(1):46-52.
doi: 10.1016/j.eururo.2016.03.026. Epub 2016 Apr 13.

Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study

Sigrid Carlsson  1 , Melissa Assel  2 , David Ulmert  3 , Axel Gerdtsson  4 , Jonas Hugosson  5 , Andrew Vickers  6 , Hans Lilja  7
Affiliations
Randomized Controlled Trial

Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study

Sigrid Carlsson et al. Eur Urol. 2017 Jan.

Abstract

Background: Current prostate cancer screening guidelines conflict with respect to the age at which to initiate screening.

Objective: To evaluate the effect of prostate-specific antigen (PSA) screening versus zero screening, starting at age 50-54 yr, on prostate cancer mortality.

Design, setting, and participants: This is a population-based cohort study comparing 3479 men aged 50 yr through 54 yr randomized to PSA-screening in the Göteborg population-based prostate cancer screening trial, initiated in 1995, versus 4060 unscreened men aged 51-55 yr providing cryopreserved blood in the population-based Malmö Preventive Project in the pre-PSA era, during 1982-1985.

Outcome measurements and statistical analysis: Cumulative incidence and incidence rate ratios of prostate cancer diagnosis, metastasis, and prostate cancer death.

Results and limitations: At 17 yr, regular PSA-screening in Göteborg of men in their early 50s carried a more than two-fold higher risk of prostate cancer diagnosis compared with the unscreened men in Malmö (incidence rate ratio [IRR] 2.56, 95% confidence interval [CI] 2.18, 3.02), but resulted in a substantial decrease in the risk of metastases (IRR 0.43, 95% CI 0.22, 0.79) and prostate cancer death (IRR 0.29, 95% CI 0.11, 0.67). There were 57 fewer prostate cancer deaths per 10000 men (95% CI 22, 92) in the screened group. At 17 yr, the number needed to invite to PSA-screening and the number needed to diagnose to prevent one prostate cancer death was 176 and 16, respectively. The study is limited by lack of treatment information and the comparison of the two different birth cohorts.

Conclusions: PSA screening for prostate cancer can decrease prostate cancer mortality among men aged 50-54 yr, with the number needed to invite and number needed to detect to prevent one prostate cancer death comparable to those previously reported from the European Randomized Study of Screening for Prostate Cancer for men aged 55-69 yr, at a similar follow-up. Guideline groups could consider whether guidelines for PSA screening should recommend starting no later than at ages 50-54 yr.

Patient summary: Guideline recommendations about the age to start prostate-specific antigen screening could be discussed.

Keywords: Prostate cancer; Prostate-specific antigen; Screening.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Cumulative risk of prostate cancer diagnosis
Light grey line: Unscreened men in Malmö Dark grey line: Men screened in Göteborg
Figure 2
Figure 2. Cumulative risk of prostate cancer metastasis
Light grey line: Unscreened men in Malmö Dark grey line: Men screened in Göteborg
Figure 3
Figure 3. Cumulative risk of prostate cancer death
Light grey line: Unscreened men in Malmö Dark grey line: Men screened in Göteborg
Figure 4
Figure 4. Cumulative risk of overall mortality
Light grey line: Unscreened men in Malmö Dark grey line: Men screened in Göteborg
See this image and copyright information in PMC

Comment in

References

    1. Moyer VA, U.S. Preventive Services Task Force Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120–34. - PubMed
    1. Heidenreich A, Abrahamsson PA, Artibani W, et al. Early detection of prostate cancer: European Association of Urology recommendation. Eur Urol. 2013;64:347–54. - PubMed
    1. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA Guideline. J Urol. 2013;190:419–26. - PMC - PubMed
    1. [Date accessed 2015-10-09];National Comprehensive Cancer Network prostate cancer screening guidelines. 2014 Available at: http://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf.
    1. Vickers AJ, Eastham JA, Scardino PT, Lilja H. The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening. Urology. 2016 Feb 2; doi: 10.1016/j.urology.2015.12.054. - DOI - PMC - PubMed

Publication types

Substances